Wednesday, September 13, 2017 4:27:49 PM
Let me get through the somewhat disappointing takeaway 1st and that is Dr. Raj saying at the Rodman & Renshaw CC that they’ll submit the Rolontis BLA in the 4th Q 2018. That’s the 1st we heard 4th Q. Why they can’t do it around the time of ASCO is beyond me. Actually, my original expectation was submitting a BLA a year earlier in late 4th Q 2017. And even though they were saying sometime in 2018 I was still thinking end of 2017 and they were just saying in 2018 to show they accomplished their goal sooner rather than later. My reasoning was based on finishing recruiting pts in September (they actually finished recruiting in early August adding salt to the wound), waiting a month to get the ANC primary and secondary endpoint data (all taken in cycle 1 or after 21 days), analyze the crap out of it for a month, and putting that data in the trial report in cookie cutter fashion which they should have been working on and ready to go beforehand and submitting it as part of an already prepared BLA package to the FDA in the 4th Q (They could almost predict what the data would be since it’s somewhat dose proportional from looking at the P2 data). While all this was going on they should have had their QA staff auditing all the patient files to make sure all was verified. They stated numerous times that they don’t need the 2nd smaller EU P3 trial which will end in the ~1st Q 2018 for the US filing so why will it take it another 9 months. Now, do you want to add another 3 months to gather safety data as Joe T indicated the other 3 cycles were for even though safety is not listed as a secondary endpoint in the protocol? Sure I’ll give you that but that’s still takes us to the end of 1st Q – beginning of 2nd Q and before ASCO. I suspect the delay has to do with the PK study they started recruiting on May 11th. Here is a previous post of mine from before the study started recruiting.
The very positive takeaway for me was Joe T, at the Annual NewsMakers in the Biotech Industry CC, explaining, how they will be differentiating the marketing of Rolontis against Neulasta and any biosimilars that pop up. And that is by Rolontis giving longer protection to the patient. I calculated 6.72 hrs for the Rolontis 4 mg Pegfilgrastim dose. Assuming dose proportionality for the 3.6 mg dose that should be about 6hrs of more protection compared to Neulasta. JT explained that to treat an infection you’re in the hospital for an average of 4.5 days getting antibiotics and that you need to get off your chemo for that time and currently that 1 in 10 pts will die of sepsis and treatment costs are high. So now we know how they are going to differentiate the product. Last week on the Seeking Alpha article by Decision Analytics, I gave an example of possible Rolontis sales of $489M as follows.
Lastly, JT mentioned they are looking to start the pozi and TDM1 combo in 2nd line breast cancer at the beginning of next year. They were mentioning this combo a lot in the 1st and 2nd Q CC even indicating they had a protocol ready to go. Then they stopped talking about it and I speculated that it was put on the back burner to make room for new pozi studies in Exon 20 insertion mutation studies and since there is only so much money to go around it was set aside. The Rolontis studies will be completing by that time so they’ll be able to dedicate their resources (money and manpower) to moving the combo study along.
Recent SPPI News
- Form 15-12G - Securities registration termination [Section 12(g)] • Edgar (US Regulatory) • 11/09/2023 10:00:17 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 09/28/2023 04:15:27 AM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 09/26/2023 09:23:08 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM